Shi-Yi Wang1, Sylvia H Hsu2, Cary P Gross3, Tara Sanft4, Amy J Davidoff5, Xiaomei Ma6, James B Yu7. 1. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA. Electronic address: shiyi.wang@yale.edu. 2. Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA; Schulich School of Business, York University, Toronto, Ontario, Canada. 3. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 4. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 5. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA. 6. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA. 7. Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Abstract
OBJECTIVES: To examine the association between time since cancer diagnosis and health-related quality of life (HRQOL) among cancer survivors in remission. METHODS: Analyzing data from 3,610 cancer survivors and 59,539 individuals without cancer in the Medical Expenditure Panel Survey, we examined the relationship between time since cancer diagnosis and HRQOL, taking remission status into account and controlling for patients' demographic characteristics and comorbidities. HRQOL measurements included the six-dimensional health state short form (derived from 36-item short form health survey) (SF-6D) utility scores, the physical component summary score, and the mental component summary score. RESULTS: The relationship between time since cancer diagnosis and HRQOL varied substantially across cancer types. Compared with individuals without cancer, survivors of breast, prostate, or poor-prognosis cancer had statistically lower SF-6D scores within 2 years of diagnosis (-0.044, -0.062, and -0.088, respectively). Breast cancer survivors had SF-6D scores similar to those of individuals without cancer after 2 years, as did patients with poor-prognosis cancer after 5 years. Nevertheless, even after a period of 10 years, survivors of prostate or cervical cancer had a lower level of SF-6D scores (-0.027 and -0.042, respectively). The comparisons of physical health between cancer survivors and individuals without cancer were similar to those of SF-6D. In contrast, most cancer survivors did not experience poorer mental health; survivors of prostate or cervical cancer, however, had lower mental component summary scores after 10 years of diagnosis. CONCLUSIONS: The level of HRQOL among cancer survivors depends on time since cancer diagnosis and cancer type. Some cancer survivors have lower HRQOL after a decade of diagnosis, even in remission.
OBJECTIVES: To examine the association between time since cancer diagnosis and health-related quality of life (HRQOL) among cancer survivors in remission. METHODS: Analyzing data from 3,610 cancer survivors and 59,539 individuals without cancer in the Medical Expenditure Panel Survey, we examined the relationship between time since cancer diagnosis and HRQOL, taking remission status into account and controlling for patients' demographic characteristics and comorbidities. HRQOL measurements included the six-dimensional health state short form (derived from 36-item short form health survey) (SF-6D) utility scores, the physical component summary score, and the mental component summary score. RESULTS: The relationship between time since cancer diagnosis and HRQOL varied substantially across cancer types. Compared with individuals without cancer, survivors of breast, prostate, or poor-prognosis cancer had statistically lower SF-6D scores within 2 years of diagnosis (-0.044, -0.062, and -0.088, respectively). Breast cancer survivors had SF-6D scores similar to those of individuals without cancer after 2 years, as did patients with poor-prognosis cancer after 5 years. Nevertheless, even after a period of 10 years, survivors of prostate or cervical cancer had a lower level of SF-6D scores (-0.027 and -0.042, respectively). The comparisons of physical health between cancer survivors and individuals without cancer were similar to those of SF-6D. In contrast, most cancer survivors did not experience poorer mental health; survivors of prostate or cervical cancer, however, had lower mental component summary scores after 10 years of diagnosis. CONCLUSIONS: The level of HRQOL among cancer survivors depends on time since cancer diagnosis and cancer type. Some cancer survivors have lower HRQOL after a decade of diagnosis, even in remission.
Authors: Amy Trentham-Dietz; Brian L Sprague; Ronald Klein; Barbara E K Klein; Karen J Cruickshanks; Dennis G Fryback; John M Hampton Journal: Breast Cancer Res Treat Date: 2007-08-03 Impact factor: 4.872
Authors: Barbara Muzzatti; Cristiana Flaiban; Antonella Surbone; Maria Antonietta Annunziata Journal: Qual Life Res Date: 2014-10-24 Impact factor: 4.147
Authors: Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson Journal: Lancet Oncol Date: 2011-08-05 Impact factor: 41.316
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Sigrid Carlsson; Linda Drevin; Stacy Loeb; Anders Widmark; Ingela Franck Lissbrant; David Robinson; Eva Johansson; Pär Stattin; Per Fransson Journal: BJU Int Date: 2015-06-23 Impact factor: 5.588
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Dzung Ngoc Thi Dang; Lan Ngoc Thi Nguyen; Nga Thi Dang; Huy Quang Dang; Thanh Van Ta Journal: Biomed Res Int Date: 2019-05-19 Impact factor: 3.411
Authors: Natalia Kunst; Shi-Yi Wang; Annette Hood; Sarah S Mougalian; Michael P DiGiovanna; Kerin Adelson; Lajos Pusztai Journal: JAMA Netw Open Date: 2020-11-02
Authors: Anouk K M Claessens; Reinier Timman; Jan J Busschbach; Jeanette M Bouma; Jeany M Rademaker-Lakhai; Frans L G Erdkamp; Vivianne C G Tjan-Heijnen; Monique E M M Bos Journal: Breast Cancer Res Treat Date: 2019-11-28 Impact factor: 4.872
Authors: Jéssica Alonso-Molero; Trinidad Dierssen-Sotos; Ines Gomez-Acebo; Nerea Fernandez de Larrea Baz; Marcela Guevara; Pilar Amiano; Gemma Castaño-Vinyals; Tania Fernandez-Villa; Victor Moreno; Juan Bayo; Ana Molina-Barceloa; María Fernández-Ortíz; Claudia Suarez-Calleja; Rafael Marcos-Gragera; Xavier Castells; Leire Gil-Majuelo; Eva Ardanaz; Beatriz Pérez-Gómez; Manolis Kogevinas; Marina Pollán; Javier Llorca Journal: Int J Environ Res Public Health Date: 2020-11-13 Impact factor: 3.390